$3.42 -0.1 -1.4%
Last Trade - 16/04/21
| Market Cap | £249.4m |
| Enterprise Value | £225.5m |
| Revenue | £113.1m |
| Position in Universe | 3973rd / 6850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 48.2 | 15.5 | 62.0 | 55.6 | 111.4 | 156.5 | 177.8 | 215.2 | +26.5% | ||
| -2.95 | +83.8 | |||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | April 18, 2002 |
| Public Since | June 25, 2002 |
| No. of Shareholders: | 110 |
| No. of Employees: | 176 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 100,861,848 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 4131 Parklake Ave Ste 225, RALEIGH, 27612-2390, United States |
| Web | https://www.bdsi.com/ |
| Phone | +1 919 5829050 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 16/04/21, shares in BioDelivery Sciences International Inc are trading at $3.42, giving the company a market capitalisation of £249.4m. This share price information is delayed by 15 minutes.
Shares in BioDelivery Sciences International Inc are currently trading at $3.42 and the price has moved by -16.89% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioDelivery Sciences International Inc price has moved by -42.71% over the past year.
Of the analysts with advisory recommendations for BioDelivery Sciences International Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioDelivery Sciences International Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
BioDelivery Sciences International Inc is scheduled to issue upcoming financial results on the following dates:
BioDelivery Sciences International Inc does not currently pay a dividend.
BioDelivery Sciences International Inc does not currently pay a dividend.
BioDelivery Sciences International Inc does not currently pay a dividend.
To buy shares in BioDelivery Sciences International Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in BioDelivery Sciences International Inc are currently trading at $3.42, giving the company a market capitalisation of £249.4m.
Here are the trading details for BioDelivery Sciences International Inc:
Based on an overall assessment of its quality, value and momentum, BioDelivery Sciences International Inc is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in BioDelivery Sciences International Inc are currently priced at $3.42. At that level they are trading at 0.107% discount to the analyst consensus target price of 0.00.
Analysts covering BioDelivery Sciences International Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.29 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioDelivery Sciences International Inc. Over the past six months, the relative strength of its shares against the market has been -23.84%. At the current price of $3.42, shares in BioDelivery Sciences International Inc are trading at -15.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioDelivery Sciences International Inc PE ratio based on its reported earnings over the past 12 months is 11.45. The shares are currently trading at $3.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioDelivery Sciences International Inc's management team is headed by:
Here are the top five shareholders of BioDelivery Sciences International Inc based on the size of their shareholding:
